PARP Inhibitors Pipeline Summary
- The Global PARP Inhibitors Pipeline is witnessing steady progress, driven by increasing research activities and the development of novel therapeutic candidates across various stages of clinical trials.
- The leading PARP Inhibitors Companies such as TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics, and others.
Request for Unlocking the Sample Page of the "PARP Inhibitors Pipeline"
DelveInsight’s, “PARP Inhibitors Pipeline Insight, 2026,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the PARP Inhibitors pipeline landscape. It covers the PARP Inhibitors Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the PARP Inhibitors Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
PARP Inhibitors Understanding
PARP Inhibitors Overview
PARP is a family of proteins loosely based on structural similarity and function. PARP proteins are composed of two ribose moieties and two phosphates per unit polymer. PARP1 and PARP2 are enzymes involved in a DNA repair pathway for SSBs called BER. The best-known PARP is PARP1. This enzyme was first reported in 1963. In 1980 Durkacz et al. proposed that modulating PARP1 might augment the effect of alkylator chemotherapy. PARP1 detects and binds to sites of single strand DNA damage via the DNA-binding domain.
It then synthesizes poly (ADP) ribose (PAR) and transfers it to acceptor proteins. PAR recruits other repair proteins to the damaged DNA site. In the case of extreme DNA damage, as with ischemia, PARP1 hyperactivation induces depletion of NAD+ and ATP, resulting in cell death by necrosis or apoptosis. PAR is involved in double strand breaks (DSBs) repair as well. PAR recruits ATM, MRE11, and topoisomerase 1, which are involved in DSBs repair.
- All current PARP inhibitors in development are thought to inhibit both PARP1 and PARP2. Though nicotinamide's activity in inhibiting PARP was first noted in 1971, the exploration of this class of agent has recently become extensive. The first generation of inhibitors included nicotinamide analogues.
- In multiple PARPi-involved combination strategies, PARPi acts as sensitizers for chemotherapies, immunotherapies, and targeted therapies by limiting DNA damage repair. In addition, some targeted treatments such as MEK inhibitors could enhance the sensitivity of tumor cells and relieve the resistance to PARPi.
Explore in-depth PARP Inhibitors Market Trends, competitive landscape, and future growth opportunities @ PARP Inhibitors Market
PARP Inhibitors Emerging Drugs Chapters
This segment of the PARP Inhibitors Pipeline Report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand PARP2 Clinical Trials details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
PARP Inhibitors Emerging Drugs Profile
-
Pamiparib: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, Tislelizumab (BGB-A317), for a variety of solid tumor malignancies
PARP Inhibitors Pipeline Therapeutic Assessment
This segment of the PARP Inhibitors Pipeline Report provides insights about the different PARP Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major PARP Inhibitors Companies
There are approx. 30+ key companies which are developing the PARP Inhibitors. The PARP Inhibitors Companies which have their PARP Inhibitors drug candidates in the most advanced stage, i.e. phase III include, BeiGene.
Phases
DelveInsight’s PARP Inhibitors Pipeline Report covers around 30+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
PARP Inhibitors Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
PARP Inhibitors Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
PARP Inhibitors Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Understand disease PARP Inhibitors Prevalence, and Patient Population trends with DelveInsight’s detailed Epidemiology Report @ PARP Inhibitors Incidence
Key PARP Inhibitors Companies
- TESARO
- AstraZeneca
- Sun BioPharma
- Eisai Co
- BeiGene
- IMPACT Therapeutics
- Ribon Therapeutics
Key PARP Inhibitors Products
- Niraparib
- Olaparib
- SBP 101
- 2X 121
PARP Inhibitors Clinical Trials Activities
The PARP Inhibitors Pipeline Report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses PARP Inhibitors Therapeutic Drugs key players involved in developing key drugs.
PARP Inhibitors Pipeline Development Activities
The PARP Inhibitors Pipeline Report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PARP Inhibitors drugs.
PARP Inhibitors Pipeline Report Highlights
- The PARP Inhibitors Companies and academics are working to assess challenges and seek opportunities that could influence PARP Inhibitors R&D. The PARP Inhibitors Therapies under development are focused on novel approaches for PARP Inhibitors.
- In July 2020: Oncology Venture announced that it has secured the remaining ownership in its priority PARP inhibitor (2X-121) program along with its 2X-111 program, by acquiring all outstanding shares in Oncology Venture US Inc. (formerly 2X Oncology, Inc.) from its external shareholders and warrantholders. As a result of the transaction, the Company now has 100 % ownership of 2X-121, which is being clinically developed as an anti-cancer therapeutic, as well as being tested as an anti-viral agent against COVID-19. Similarly, the Company now has 100% ownership of 2X-111, which is being clinically developed as an anti-cancer therapeutic via a recently announced license agreement with Smerud Medical Research International.
PARP Inhibitors Pipeline Report Insights
- PARP Inhibitors Pipeline Analysis
- PARP Inhibitors Therapeutic Assessment
- PARP Inhibitors Unmet Needs
- Impact of PARP Inhibitors Drugs
PARP Inhibitors Pipeline Report Assessment
- PARP Inhibitors Pipeline Product Profiles
- PARP Inhibitors Therapeutic Assessment
- PARP Inhibitors Pipeline Assessment
- Inactive PARP Inhibitors Drugs assessment
- PARP Inhibitors Unmet Needs
Key Questions Answered in the PARP Inhibitors Pipeline Report
Current PARP Inhibitors Treatment Scenario and PARP Inhibitors Emerging Therapies:
- How many companies are developing PARP inhibitor drugs?
- How many PARP Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for PARP Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the PARP Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the PARP Inhibitors Clinical Trials going on and their status?
- What are the key designations that have been granted to the PARP Inhibitors emerging drugs?
Stay updated with us for Recent Articles
